Ondas Holdings stock rises premarket after $1 billion deal closes, with warrants and Jan. 16 investor day in focus
13 January 2026
2 mins read

Ondas Holdings stock rises premarket after $1 billion deal closes, with warrants and Jan. 16 investor day in focus

New York, Jan 13, 2026, 08:36 EST — Premarket

  • ONDS climbed 1.3% in premarket trading after the company confirmed it completed a $1 billion stock-and-warrant offering
  • The financing comes with warrants linked to 121.6 million shares, posing a potential dilution risk.
  • Traders are eyeing Ondas’ slot at the Needham conference on Jan. 14 and a virtual investor day set for Jan. 16

Shares of Ondas Holdings Inc (ONDS) climbed 1.3% in premarket Tuesday following the completion of a $1 billion stock-and-warrant offering. The stock last traded at $13.36. (Public)

The cash injection arms Ondas with fresh firepower for acquisitions and investments, right as small-cap drone and defense tech stocks buzz with capital raises and deal rumors. The downside is clear: issuing more shares means added complexity and less tolerance from investors if that money doesn’t translate into signed contracts.

The announcement arrives mere days ahead of two investor-facing events, where management must clearly link the financing to future plans. Traders usually probe these narratives right at the open, not through a slide deck presentation.

Ondas announced the sale of 19 million shares along with pre-funded warrants for up to 41.79 million shares, pricing units at roughly $16.45 each—17.5% above the Jan. 8 closing price. Each unit includes a warrant to purchase two additional shares. The company expects net proceeds to hit around $959.2 million, earmarked for corporate development and strategic growth, including acquisitions, joint ventures, and investments. The warrants attached cover 121.58 million shares, are exercisable immediately at $28 per share for seven years, and could potentially generate $3.4 billion if fully exercised, though Ondas cautioned that outcome isn’t guaranteed. (Nasdaq)

A pre-funded warrant acts as a nearly fully paid placeholder for stock: the buyer shells out most of the cash upfront and can convert it into shares down the line. In contrast, a common stock warrant works like an option — it grants the right to purchase shares at a set price but doesn’t require the buyer to do so.

Ondas closed Monday down 3.65% at $13.19, after fluctuating between $12.83 and $15.28. Roughly 121 million shares changed hands, per market data. (Investing)

The gap between Monday’s close and the $16.45 sale price hangs like a scoreboard. It could narrow fast if the company lands a deal or a major client. Or it might widen if investors see the offering as nothing more than dilution dressed up.

Ondas offers autonomous drone systems via its Ondas Autonomous Systems unit and private wireless gear through Ondas Networks. The company is scheduled to present at the Needham Growth Conference on Jan. 14 at 8:45 a.m. EST, its investor site shows. (Ondas Holdings Inc.)

Ondas plans to hold a virtual investor day at 10:00 a.m. EST on Jan. 16, just two days from now. (Ondas Holdings Inc.)

Tradr ETFs is rolling out a 2x leveraged ETF tied to Ondas, with trading set to start on Cboe Tuesday. “This newest suite of funds touches on … drone technology,” said Matt Markiewicz, head of product and capital markets at Tradr ETFs. Leveraged ETFs aim to multiply a stock’s daily moves but reset every day, making them tricky for long-term holding. (PR Newswire)

Risks loom directly over the catalysts. The hefty warrant load might limit any rally, and if shares fail to approach $28, that “extra” $3.4 billion remains nothing more than a figure on paper. If deal-making is in the cards, integration and timing challenges come into play.

Stock Market Today

  • Tempus expands oncology collaborations with NYU Langone and Northwestern Medicine; stock up 114%
    January 13, 2026, 9:11 AM EST. Tempus AI TEM expanded collaborations with leading centers to broaden access to genomic testing and data-driven cancer care. A multi-year deal with NYU Langone Health will advance genetic testing and data analysis to improve diagnostics, guide treatment and speed new test development. TEM will also support test validation, biomarker discovery, disease modeling, real-world data analysis and AI-driven prediction tools at the Perlmutter Cancer Center. In a separate pact, Northwestern Medicine will broaden genomic testing for more cancer patients, including early-stage cases, covering tissue testing, DNA and RNA profiling, liquid biopsy and MRD testing. The market note cites Illumina's TSO 500 v2 with HRD detection and CDx; and Myriad's Precise Liquid and Precise MRD. TEM shares up 114.3% year over year; the S&P 500 up about 22% in the period.
Plug Power stock ticks up in premarket as UBS conference meetings put strategy back in focus
Previous Story

Plug Power stock ticks up in premarket as UBS conference meetings put strategy back in focus

Go toTop